Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
science & technology (20) 20
oncology (19) 19
life sciences & biomedicine (18) 18
male (13) 13
biological and medical sciences (12) 12
medical sciences (11) 11
female (10) 10
lung neoplasms - drug therapy (10) 10
animals (9) 9
aged (8) 8
tumors (8) 8
adult (7) 7
lung neoplasms - pathology (7) 7
mice (7) 7
middle aged (7) 7
carcinoma, non-small-cell lung - drug therapy (6) 6
lung cancer (6) 6
lung cancer, non-small cell (6) 6
antineoplastic agents (5) 5
cancer (5) 5
care and treatment (5) 5
chemotherapy (5) 5
lung neoplasms - therapy (5) 5
pharmacology. drug treatments (5) 5
carcinoma, non-small-cell lung - genetics (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
carcinoma, non-small-cell lung - therapy (4) 4
genetic therapy - methods (4) 4
health aspects (4) 4
lung neoplasms - genetics (4) 4
lung neoplasms - mortality (4) 4
pharmacology & pharmacy (4) 4
pneumology (4) 4
receptor, epidermal growth factor - antagonists & inhibitors (4) 4
treatment outcome (4) 4
tumors of the respiratory system and mediastinum (4) 4
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer therapies (3) 3
genetics (3) 3
immunotherapy (3) 3
liposomes (3) 3
medicine & public health (3) 3
molecular targeted therapy (3) 3
research (3) 3
survival analysis (3) 3
survival rate (3) 3
tumor cells, cultured (3) 3
usage (3) 3
adenoviridae - genetics (2) 2
administration, inhalation (2) 2
aged, 80 and over (2) 2
analysis (2) 2
animal models (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibodies, monoclonal, humanized (2) 2
antineoplastic agents, phytogenic - adverse effects (2) 2
antineoplastic agents, phytogenic - therapeutic use (2) 2
biology and life sciences (2) 2
biotechnology & applied microbiology (2) 2
cancer treatment (2) 2
carcinoma, non-small-cell lung - metabolism (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
carcinoma, squamous cell - drug therapy (2) 2
cations (2) 2
cell line, tumor (2) 2
complications and side effects (2) 2
cytotoxicity (2) 2
deoxyribonucleic acid--dna (2) 2
dosage and administration (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
drug carriers (2) 2
drug resistance (2) 2
epidermal growth factor (2) 2
erlotinib (2) 2
erlotinib hydrochloride (2) 2
follow-up studies (2) 2
gene expression (2) 2
gene transfer techniques (2) 2
genes (2) 2
genes, p53 - genetics (2) 2
genetic aspects (2) 2
genetics & heredity (2) 2
immunohistochemistry (2) 2
lung neoplasms - immunology (2) 2
lung neoplasms - metabolism (2) 2
medical prognosis (2) 2
medicine (2) 2
medicine and health sciences (2) 2
medicine, research & experimental (2) 2
metastasis (2) 2
mice, inbred icr (2) 2
mice, nude (2) 2
multidisciplinary sciences (2) 2
mutation (2) 2
neoplasm metastasis (2) 2
neoplasm staging (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Leptomeningeal metastases in non-small-cell lung cancer
by Cheng, Haiying and Perez-Soler, Roman
The lancet oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. e43 - e55
Life Sciences & Biomedicine | Oncology | Science & Technology | Medical colleges | Analysis | Therapeutics | Metastasis | Lung cancer, Non-small cell | Health aspects | Homeopathy | Materia medica and therapeutics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
by Román Pérez-Soler and Abraham Chachoua and Lisa A. Hammond and Eric K. Rowinsky and Mark Huberman and Daniel Karp and James Rigas and Gary M. Clark and Pedro Santabárbara and Philip Bonomi
Journal of clinical oncology, ISSN 0732-183X, 08/2004, Volume 22, Issue 16, pp. 3238 - 3247
Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Carcinoma, Non-Small-Cell Lung - pathology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Administration, Oral | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Treatment Outcome | Diarrhea - chemically induced | Exanthema - chemically induced | Quinazolines - adverse effects | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
by Román Peréz-Soler and Leonard Saltz
Journal of clinical oncology, ISSN 0732-183X, 08/2005, Volume 23, Issue 22, pp. 5235 - 5246
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Erlotinib Hydrochloride | Prognosis | Biomarkers, Tumor - analysis | Exanthema | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cetuximab | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials
by Shum, Elaine and Wang, Feng and Kim, Salem and Perez-Soler, Roman and Cheng, Haiying
Expert opinion on investigational drugs, ISSN 1354-3784, 04/2017, Volume 26, Issue 4, pp. 415 - 426
targeted therapy | Squamous cell lung cancer | novel therapy | immunotherapy | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Lung Neoplasms - drug therapy | Immunotherapy - methods | Drugs, Investigational - pharmacology | Carcinoma, Squamous Cell - pathology | Humans | Drugs, Investigational - therapeutic use | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Animals | Carcinoma, Squamous Cell - drug therapy | Drug Design | Antineoplastic Agents - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma
by Charles Lu and Roman Perez-Soler and Bilal Piperdi and Garrett L. Walsh and Stephen G. Swisher and W. Roy Smythe and Hyung J. Shin and Jae Y. Ro and Lei Feng and Mylene Truong and Adiseshu Yalamanchili and Gabriel Lopez-Berestein and Waun K. Hong and Abdul R. Khokhar and Dong M. Shin
Journal of clinical oncology, ISSN 0732-183X, 05/2005, Volume 23, Issue 15, pp. 3495 - 3501
Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Immunohistochemistry | Follow-Up Studies | Mesothelioma - pathology | Humans | Middle Aged | Male | Mesothelioma - mortality | Drug Carriers | Pleural Neoplasms - drug therapy | Dose-Response Relationship, Drug | Organoplatinum Compounds - administration & dosage | Mesothelioma - surgery | Aged, 80 and over | Adult | Female | Pleural Neoplasms - pathology | Drug Administration Schedule | Risk Assessment | Pleural Neoplasms - surgery | Probability | Survival Rate | Treatment Outcome | Pleural Neoplasms - mortality | Mesothelioma - drug therapy | Aged | Biopsy, Needle | Liposomes | Neoplasm Staging | Chemotherapy, Cancer, Regional Perfusion | Organoplatinum Compounds - adverse effects | Thoracoscopy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Targeting angiogenesis in squamous non-small cell lung cancer
by Piperdi, Bilal and Merla, Amartej and Perez-Soler, Roman
Drugs (New York, N.Y.), ISSN 0012-6667, 2014, Volume 74, Issue 4, pp. 403 - 413
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - blood supply | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Clinical Trials as Topic | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Molecular Targeted Therapy | Angiogenesis Inhibitors - administration & dosage | Animals | Carcinoma, Squamous Cell - drug therapy | Neovascularization, Pathologic - drug therapy | Lung - drug effects | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Squamous Cell - blood supply | Neovascularization, Pathologic - metabolism | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung - blood supply | Drug Screening Assays, Antitumor | Lung Neoplasms - blood supply
Journal Article
Details down arrow
7. Full Text Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine
by Qiu, Xuan and Liang, Yuanxin and Sellers, Rani S and Perez-Soler, Roman and Zou, Yiyu
Clinical lung cancer, ISSN 1525-7304, 2015, Volume 17, Issue 3, pp. 214 - 222.e1
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Demethylating agent | Circulation drug levels | Pulmonary and bone marrow toxicities | Lung deposition | Inhalation | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Administration, Intravenous | Azacitidine - pharmacokinetics | Animals | Humans | Administration, Inhalation | Female | Male | Lung - metabolism | Mice | Leukocytes - metabolism | Mice, Inbred ICR | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Aerosol azacytidine inhibits orthotopic lung cancers in mice through its DNA demethylation and gene reactivation effects
by Qiu, Xuan and Liang, Yuanxin and Sellers, Rani S and Perez-Soler, Roman and Zou, Yiyu
PloS one, ISSN 1932-6203, 10/2014, Volume 9, Issue 10, pp. e109874 - e109874
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Promoter Regions, Genetic | Azacitidine - adverse effects | Lung Neoplasms - mortality | Transcriptional Activation - drug effects | Administration, Inhalation | Lung Neoplasms - pathology | Male | Antimetabolites, Antineoplastic - administration & dosage | Xenograft Model Antitumor Assays | Animals | Tumor Suppressor Proteins - genetics | Antimetabolites, Antineoplastic - adverse effects | Cell Line, Tumor | Female | Mice | DNA Methylation - drug effects | Azacitidine - administration & dosage | Disease Models, Animal | Genes | DNA | Genetic aspects | Methylation | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Cancer | Cell culture | Azacytidine | Animal models | Intravenous administration | Toxicity | Xenotransplantation | Lung cancer | Cytotoxicity | Oncology | Activation | Cancer therapies | Proteins | Respiratory tract | Demethylation | Carcinogens | Inoculation | Xenografts | DNA methylation | Dosimetry | Lesions | Trachea | Deposition | Deoxyribonucleic acid--DNA | Non-small cell lung carcinoma | Pharmacology | Gene expression | Medicine | Medical prognosis | Epigenetics | Aerosols | Protein expression | Tumor suppressor genes | Laboratory animals | Tumors | Index Medicus | Deoxyribonucleic acid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer
by Bakirhan, Kamila and Sharma, Janaki and Perez-Soler, Roman and Cheng, Haiying
Current treatment options in oncology, ISSN 1527-2729, 3/2016, Volume 17, Issue 3, pp. 1 - 22
Oncology | Chemotherapy | Medicine & Public Health | Elderly | Non-small cell lung cancer | Life Sciences & Biomedicine | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Geriatric Assessment | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Vinblastine - therapeutic use | Molecular Targeted Therapy | Taxoids - therapeutic use | Deoxycytidine - therapeutic use | B7-H1 Antigen - antagonists & inhibitors | Vinblastine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Aged, 80 and over | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Complications and side effects | Usage | Care and treatment | Comorbidity | Aged patients | Research | Lung cancer, Non-small cell | Health aspects | Risk factors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
by Fossella, Frank V and Lee, Jin Soo and Shin, Dong M and Calayag, Maria and Huber, Martin and Perez-Soler, Roman and Murphy, William K and Lippman, Scott and Benner, Steven and Glisson, Bonnie and Chasen, Marvin and Hong, Waun Ki and Raber, Martin
Journal of clinical oncology, ISSN 0732-183X, 1995, Volume 13, Issue 3, pp. 645 - 651
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Neoplasm Metastasis | Carboplatin - therapeutic use | Taxoids | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Neutropenia - chemically induced | Drug Resistance | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Drug Hypersensitivity - etiology | Paclitaxel - analogs & derivatives | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Paclitaxel - therapeutic use | Remission Induction | Cisplatin - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Index Medicus
Journal Article
Details down arrow
11. Full Text The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene
by Diaz, Roberto and Diaz, Roberto and Ahn, Daniel and Ahn, Daniel and Lopez-Barcons, Lluis and Lopez-Barcons, Lluis and Malumbres, Marcos and Malumbres, Marcos and De Castro, Ignacio Perez and De Castro, Ignacio Perez and Lue, Jeffrey and Lue, Jeffrey and Ferrer-Miralles, Neus and Ferrer-Miralles, Neus and Mangues, Ramon and Mangues, Ramon and Tsong, Jerry and Tsong, Jerry and Garcia, Roberto and Garcia, Roberto and Perez-Soler, Roman and Perez-Soler, Roman and Pellicer, Angel and Pellicer, Angel
Cancer research (Chicago, Ill.), ISSN 0008-5472, 08/2002, Volume 62, Issue 15, pp. 4514 - 4518
Life Sciences & Biomedicine | Oncology | Science & Technology | Fundamental and applied b